Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer

Highlights • Prognosis remains poor for patients with metastatic squamous (sq.) NSCLC. • 2nd and 3rd chemotherapy lines are not necessarily consistent with NCCN guidelines. • Direct per-patient medical costs of metastatic sq. NSCLC are substantial. • Metastatic sq. NSCLC contributes 14–40% of total...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-02, Vol.87 (2), p.176-185
Main Authors: Davis, Keith L, Goyal, Ravi K, Able, Stephen L, Brown, Jacqueline, Li, Li, Kaye, James A
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - epidemiology
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Comorbidity
Costs
Female
Follow-Up Studies
Health Care Costs
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Lung Neoplasms - epidemiology
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Medicare
Neoplasm Staging
Patient Acceptance of Health Care
Population Surveillance
Practice Patterns, Physicians
Pulmonary/Respiratory
Resource utilization
SEER Program
Squamous non-small cell lung cancer
Survival
Treatment patterns
Tumor Burden
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Prognosis remains poor for patients with metastatic squamous (sq.) NSCLC. • 2nd and 3rd chemotherapy lines are not necessarily consistent with NCCN guidelines. • Direct per-patient medical costs of metastatic sq. NSCLC are substantial. • Metastatic sq. NSCLC contributes 14–40% of total Medicare spending on lung cancer. • First study to report the economic burden of metastatic sq. NSCLC in Medicare.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2014.11.002